BioNTech SE reported second-quarter 2025 revenue of €260.8 million, almost doubling market expectations of roughly €149 million, as the German drug maker works to transition from Covid-19 vaccines to a broader oncology and infectious-disease pipeline. The company posted a net loss of €386.6 million, or €1.60 a share, wider than the prior-year period and slightly below the average analyst estimate of a €1.41 loss. Operating loss came in at €501.1 million, narrower than the €710.1 million loss analysts had projected. The Mainz-based company kept its full-year outlook unchanged, projecting 2025 revenue between €1.70 billion and €2.20 billion and operating expenses of €2.60 billion to €2.80 billion. BioNTech ended the quarter with a cash and securities balance of €16.0 billion, which it said provides ample flexibility to fund clinical trials and potential acquisitions aimed at expanding its oncology portfolio.
$W +9.65% [Wayfair's Q2 2025 results show net revenue of $3.3B (consensus $3.1B), up 5% y/y. They reported net income of $15M and Adjusted EBITDA of $205M (6.3% margin). This marks their highest revenue growth and profitability since 2021.] https://t.co/RDZG3AAeIF https://t.co/nySX3B5Zrp
$W Wayfair reports Q2 adjusted EPS 87c, consensus 33cReports Q2 revenue $3.3B, consensus $3.12B. "
Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results $TWST https://t.co/U7GVPfeffE